Senate expected to pass House user fee bill

On Wednesday, the House of Representatives passed the FDA Reauthorization Act of 2017 (FDARA), which reauthorizes PDUFA and user fees for biosimilars, generic drugs and medical devices. House and Senate committees with jurisdiction over FDA agreed on the final language, so the Senate is expected to enact the House-passed bill with no changes, a House Energy & Commerce Democratic spokesperson told BioCentury. “We pre-conferenced with the Senate," he said. "The idea is the bill the House passed today will be passed by the Senate."

Late Wednesday, however, Sen. Ron Johnson (R-Wis.) said he would hold up the legislation's passage if it is not amended to include a right-to-try provision...